A.I. Burnasyan  FMBC clinical bulletin. 2023 № 2

 

M. B. Mungieva, E. E. Norzhilova, E.A. Dubova, K.A. Pavlov

Fibrolamellar Hepatocellular Carcinoma: Case Report and Literature Review

A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia

Contact person: Mungieva Maiya Batirbekovna: mungieva.maiya@yandex.ru

Abstract
Fibrolamellar carcinoma of liver – rare and poorly understood variant of hepatocellular carcinoma with unique morphology and molecular biology. Here we present a literature review and a case report of fibrolamellar carcinoma in a 29 y.o. male. Problems of a preoperative diagnosis are shown and morphological criteria are giver together with differentials.

Keywords: fibrolamellar carcinoma, hepatocellular carcinoma, livery

For citation: Mungieva MB, Norzhilova EE, Dubova EA, Pavlov KA. Fibrolamellar Hepatocellular Carcinoma: Case Report and Literature Review. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2023.2:34-37. (In Russian) DOI: 10.33266/2782-6430-2023-2-34-37

 

REFERENCES

1. Abdelhamed W., El-Kassas M. Fibrolamellar Hepatocellular Carcinoma: A Rare But Unpleasant Event. World J. Gastrointest Oncol. 2022;14;6:1103-1114. doi: 10.4251/wjgo.v14.i6.1103.

2. Шавочкина Д.А., Кустова И.Ф., Лазаревич Н.Л. Фиброламеллярная карцинома как отдельный подтип гепатоцеллюлярного рака: молекулярно-генетические особенности, диагностика, перспективы лечения // Злокачественные опухоли. 2017. Т.7, № 3. С. 71–80. doi:10.18027 / 2224–5057–2017–7–3–71–80. [Shavochkina D.A., Kustova I.F., Lazarevich N.L. Fibrolamellar Carcinoma as a Distinct Subtype of Hepatocellular Carcinoma: Molecular Genetics Features, Diagnostics And Treatment Prospects. Zlokachestvennyye Opuholi = Malignant Tumoursis. 2017;3:71–80. doi: 10.18027 / 2224–5057–2017–7–3–71–80 (In Russ.)].

3. Bauer J., Köhler N., Maringer Y., Bucher P., Bilich T., Zwick M., Dicks S., Nelde A., Dubbelaar M., Scheid J., Wacker M., Heitmann J.S., Schroeder S., Rieth J., Denk M., Richter M., Klein R., Bonzheim I., Luibrand J., Holzer U., Ebinger M., Brecht I.B., Bitzer M., Boerries M., Feucht J., Salih H.R., Rammensee H.G., Hailfinger S., Walz J.S. The Oncogenic Fusion Protein DNAJB1-PRKACA Can Be Specifically Targeted by Peptide-Based Immunotherapy in Fibrolamellar Hepatocellular Carcinoma. Nat. Commun. 2022;13;1:6401. doi: 10.1038/s41467-022-33746-3.

4. Polychronidis G., Feng J., Murtha-Lemekhova A., Heger U., Mehrabi A., Hoffmann K. Factors Influencing Overall Survival for Patients with Fibrolamellar Hepatocellular Carcinoma: Analysis of the Surveillance, Epidemiology, and End Results Database. Int. J. Gen. Med. 2022;15:393-406. doi: 10.2147/IJGM.S338066.

5. Cornella H., Alsinet C., Sayols S., Zhang Z., Hao K., Cabellos L., Hoshida Y., Villanueva A., Thung S., Ward S.C., Rodriguez-Carunchio L., Vila-Casadesús M., Imbeaud S., Lachenmayer A., Quaglia A., Nagorney D.M., Minguez B., Carrilho F., Roberts L.R., Waxman S., Mazzaferro V., Schwartz M., Esteller M., Heaton N.D., Zucman-Rossi J., Llovet J.M. Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology. 2015;148;4:806-818.e10. doi: 10.1053/j.gastro.2014.12.028.

6. Graham R.P., Yeh M.M., Lam-Himlin D., Roberts L.R., Terracciano L., Cruise M.W., Greipp P.T., Zreik R.T., Jain D., Zaid N., Salaria S.N., Jin L., Wang X., Rustin J.G., Kerr S.E., Sukov W.R., Solomon D.A., Kakar S., Waterhouse E., Gill R.M., Ferrell L., Alves V.A., Nart D., Yilmaz F., Roessler S., Longerich T., Schirmacher P., Torbenson M.S. Molecular Testing for the Clinical Diagnosis of Fibrolamellar Carcinoma. Mod. Pathol. 2018;31;1:141-149. doi: 10.1038/modpathol.2017.103.

7. Calderaro J., Couchy G., Imbeaud S., Amaddeo G., Letouzé E., Blanc J.F., Laurent C., Hajji Y., Azoulay D., Bioulac-Sage P., Nault J.C., Zucman-Rossi J. Histological Subtypes of Hepatocellular Carcinoma Are Related to Gene Mutations and Molecular Tumour Classification. J. Hepatol. 2017;67;4:727-738. doi: 10.1016/j.jhep.2017.05.014.

8. Tanaka H., Hijioka S., Iwaya H., Mizuno N., Kuwahara T., Okuno N., Ito A., Kuraoka N., Matsumoto S., Obata M., Kurita Y., Yasuda M., Shimizu Y., Kuroda H., Sato Y., Haneda M., Sasaki E., Yatabe Y., Hara K. Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy.Intern. Med. 2018;57;24:3537-3543. doi: 10.2169/internalmedicine.1243-18.

9. Chakrabarti S., Tella S.H., Kommalapati A., Huffman B.M., Yadav S., Riaz I.B., Goyal G., Mody K., Borad M., Cleary S., Smoot R.L., Mahipal A. Clinicopathological Features and Outcomes of Fibrolamellar Hepatocellular Carcinoma. J. Gastrointest Oncol. 2019;10;3:554-561. doi: 10.21037/jgo.2019.01.35.

10. Ross H.M., Daniel H.D., Vivekanandan P., Kannangai R., Yeh M.M., Wu T.T., Makhlouf H.R., Torbenson M. Fibrolamellar Carcinomas Are Positive for CD68. Mod. Pathol. 2011;24;3:390-395. doi: 10.1038/modpathol.2010.207.

11. Ang C.S., Kelley R.K., Choti M.A., Cosgrove D.P., Chou J.F., Klimstra D., Torbenson M.S., Ferrell L., Pawlik T.M., Fong Y., O’Reilly E.M., Ma J., McGuire J., Vallarapu G.P., Griffin A., Stipa F., Capanu M., Dematteo R.P., Venook A.P., Abou-Alfa G.K. Clinicopathologic Characteristics and Survival Outcomes of Patients with Fibrolamellar Carcinoma: Data from the Fibrolamellar Carcinoma Consortium. Gastrointest Cancer Res. 2013;6;1:3-9.

12. Ganeshan D., Szklaruk J., Kaseb A., Kattan A., Elsayes K.M. Fibrolamellar Hepatocellular Carcinoma: Multiphasic CT Features of the Primary Tumor on Pre-Therapy CT and Pattern of Distant Metastases. Abdom Radiol (NY). 2018;43;12:3340-3348. doi: 10.1007/s00261-018-1657-2.

13. Wahab M.A., El Hanafy E., El Nakeeb A., Ali M.A. Clinicopathological Features and Surgical Outcome of Patients with Fibrolamellar Hepatocellular Carcinoma (Experience with 22 Patients over a 15-Year Period). World J. Gastrointest Surg. 2017;9;2:61-67. doi: 10.4240/wjgs.v9.i2.61.

14. Ward S.C., Huang J., Tickoo S.K., Thung S.N., Ladanyi M., Klimstra D.S. Fibrolamellar Carcinoma of the Liver Exhibits Immunohistochemical Evidence of Both Hepatocyte and Bile Duct Differentiation. Mod. Pathol. 2010;23;9:1180-1190. doi: 10.1038/modpathol.2010.105.

15. Honeyman J.N., Simon E.P., Robine N., Chiaroni-Clarke R., Darcy D.G., Lim I.I., Gleason C.E., Murphy J.M., Rosenberg B.R., Teegan L., Takacs C.N., Botero S., Belote R., Germer S., Emde A.K., Vacic V., Bhanot U., LaQuaglia M.P., Simon S.M. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma. Science. 2014;343;6174:1010-1014. doi: 10.1126/science.1249484.

 

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship. 
Contribution. Article was prepared with equal participation of the authors.
Article received: 28.04.2023. Accepted for publication: 20.05.2023